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Abstract Measles virus (MV) persistence in brain cells has 
broad effects on different cellular functions. We have previously 
shown that NS20Y clone, originally derived from C1300 
neuroblastoma cells, persistently infected with MV (NS20Y/ 
MS), displays constitutively elevated levels of c-fos and PKC 
mRNAs, implying MV-mediated effects on transcriptional 
regulation. Nonetheless, the mode by which virus affects the 
transcriptional machinery still remains obscure. In order to 
define this phenomenon, we studied the binding properties of 
major transcription factors (AP-1 and NFKB) in NS20Y/MS 
cells. Using electrophoretic mobility shift approach (EMSA) 
with the appropriate oligonucleotide probes, we have found that 
the persistent MV infection does not affect NFKB binding, while 
the AP-1 binding was significantly decreased. Similar inhibition 
was not observed in NS20Y cells acutely infected with MV. Anti-
measles antibody-mediated restriction of viral gene expression 
restored AP-1 binding, thus suggesting that measles virus 
proteins may affect the components of the host transcriptional 
machinery. 
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1. Introduction 
Measles virus (MV) is a common human pathogen respon-
sible for an acute epidemic disease with a worldwide preva-
lence. It is also associated with subacute sclerosing panence-
phalytis (SSPE) and measles inclusion bodies encephalytis 
(MIBE) that occur months to years after onset of acute mea-
sles on the basis of MV persistence in brain cells [1]. Although 
the molecular basis of persistent infection was characterized 
by alterations of viral gene expression on the transcriptional 
and translational levels and morphological pictures of the 
both SSPE and MIBE were described, little is known about 
the molecular basis of MV-mediated cytopathic effects in the 
brain [2-4]. 
We have previously demonstrated that the persistent infec-
tion of murine neuroblastoma cells with MV resulted in a 
spectrum of changes in the expression of cellular genes, i.e., 
an enhanced transcription of c-fos and PKC genes, a dimin-
ished level of Ha-ras mRNA [5] and elevated level of MHC 
class I glycoproteins on plasma membrane [6]. These observa-
tions imply MV-mediated effects on gene expression in host 
cells. 
Regulation of gene expression in nucleus occurs via modu-
lation of transcription factors activity. The ubiquitous tran-
scription factor, activating protein 1 (AP-1), regulates the 
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transcription of a variety of genes. AP-1 is constituted by 
the products of Jun family proteins, including c-Jun, Jun-B 
and Jun-D, and the products of Fos family (c-Fos, Fos-B, 
Fra-1 and Fra-2) [7]. In response to the appropriate signal, 
such as phorbol esters, growth factors and other mitogenic 
agents, activated Fos/Jun or Jun/Jun dimers bind to the pal-
indromic sequence TGAC/GTCA present in the promoters of 
a number of genes induced by phorbol esters and, thereby, 
known as TPA responsive element (TRE) [8,9]. Functional 
specificity of different Fos and Jun families is most likely 
determined by their differential distribution and inducibility. 
These proteins act as cell-specific nuclear third messengers 
converting cytoplasmatic signals into long-term adaptive 
changes in cell phenotype by regulating the expression of spe-
cific target genes [7]. 
c-Fos is induced in many different cell types by a wide 
variety of signals and is involved in cell proliferation, differ-
entiation, neuronal excitation and other basic processes [10-
12]. Different receptor-second messenger systems can modu-
late the composition of Fos/Jun dimers thereby regulating the 
expression of distinct subsets of genes. Most neuronal tissues 
express low basal levels of AP-1 transcription factors, which 
dramatically increase after a strong stimuli [12]. The induction 
of Fos and Jun proteins was well studied in striatum and 
hyppocampus, AP-1 was shown to be involved in regulation 
of circadian pacemaking system, in modulation of the behav-
ioral rhythms, in biochemical processes underlying learning 
and memory [13-15]. Given the marked elevation in c-fos 
mRNA in MV persistently infected cells, we wished to deter-
mine whether these changes will affect DNA-binding capacity 
of AP-1 transcription factor complex. Here we present the 
results describing the effect of the persistent MV infection 
on the level of Fos and Jun proteins and on the DNA-binding 
activity of AP-1 transcription regulatory complex in persist-
ently infected cells of neuronal origin. 
2. Materials and methods 
2.1. Cells lines 
The C1300 neuroblastoma, clone NS20Y, of the A/J mouse strain 
was used. The establishment of MV persistently infected NS20Y cell 
clone, termed NS20Y/MS, was described in detail elsewhere [16]. Un-
infected or infected cells were routinely grown in Dulbecco's modifi-
cation of Eagle's tissue culture medium (DMEM; Beit Haemek, Isra-
el) supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% 
glutamine and 1% antibiotics. For acute infection, NS20Y cells were 
infected with 5X104 pfu of the Edmonston strain of MV and har-
vested 72 h later as previously described [17]. 
2.2. Antibodies 
The following commercial monoclonal antibodies (mAb) were used: 
c-Fos, FosB, Fra-1, Fra-2, c-Jun (Oncogene Sci., Uniodale, NY, 
USA), JunB, JunD (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA). mAbs against measles virus nucleocapsid protein (MV N) 
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were described by Birrer et al. [18]. Anti-MV H mAb (hybridoma 
clones: L77, K83 and NC32) and anti-MV N were raised and kindly 
provided by V. ter Meulen [19,20]. Anti-MV N monoclonal antibody 
was a gift from Dr. V. ter Meulen. 
2.3. Anti-MV antibody treatment of cells 
For antibody (Ab) treatment, the medium of semiconfluent cultures 
was replaced with fresh medium containing a mixture of monoclonal 
neutralizing anti-H mAbs (L77, NC32, and K83), sufficient to neu-
tralize 100 pfu of MV in a conventional Vero cell neutralization assay 
[21]. The cells were split once every 3 days and fresh mAb-containing 
medium was added. Untreated and Ab-treated cells were harvested at 
different time intervals after initiation of Ab treatment, and cell ly-
sates were prepared. 
2.4. Preparation of total cell lysates 
Cells were washed by phosphate-buffered saline (PBS) and lysed in 
boiling lysis buffer (10 mM Tris-HCl (pH 8), 1% SDS). Following 
additional boiling for 5 min, lysates were passed several times through 
a needle and clarified by centrifugation at 12000Xg for 5 min. 
2.5. Western blot analysis 
Cell lysates were mixed with Laemmli sample buffer and boiled for 
5 min. Protein samples containing equal amounts of protein (50 |ig) 
were separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and subjected to Western blotting analysis in the following 
manner. The resolved proteins were transferred to nitrocellulose mem-
brane (Schleicher and Schuell, Keene, NH, USA), non-specific bind-
ing sites were blocked with 5% low-fat dry milk in PBS containing 
0.05% Tween-20 for 1 h at room temperature, followed by incubation 
with primary antibody. The strips were washed in PBS-0.05% Tween-
20 and incubated with peroxidase-conjugated secondary antibody 
(Amersham Life Sciences, Amersham, UK) for an additional 1 h. 
After washing in PBS-0.05%) Tween-20, immunoreactive proteins 
were visualized using enhanced chemiluminescence kit (Amersham 
Life Sciences). 
2.6. Oligonucleotides and electrophoretic mobility shift assay (EMSA) 
The following consensus sequence oligonucleotides were used in this 
assay: monomeric TRE:5'-CGCTTGATGACTCAGCCGGAA-3' 
(Santa Cruz Biotechnology), TRE tetramer: 5'-TGACTCA TGACT-
CA TGACTCA TGACTCA-3' (kindly provided by Dr. P. Kouril-
ski), TRE-like consensus sequence derived from murine c-jun pro-
moter: 5'-GATCCCTCGGGTGACATCACTAG-3' [22] and NFKB 
consensus sequence derived from human IL-2 promoter: 5'-GATCC-
GAAAGAGGGATTTCACCTG-3' [23]. Preparation of nuclear ly-
sates and electrophoretic mobility shift assay were performed as de-
scribed elsewhere [24]. 
3. Results 
The expression of the Fos proteins (c-Fos, Fos-B, Fra-1 and 
Fra-2) and the Jun family proteins (c-Jun, Jun-B and Jun-D) 
was analyzed by Western blotting with the appropriate mono-
clonal antibodies. A slight increase in the expression of c-Fos 
was detected in the total cell lysates of persistently infected 
NS20Y/MS cells (Fig. 1). No differences in the expression of 
either Fos-B or Fra-1 proteins were observed in total cell 
lysates of NS20Y/MS or NS20Y cells. Fra-2 protein was un-
detectable in both cell lines. Jun-B protein expressed at rela-
tively high level in NS20Y cells was significantly down-regu-
lated in NS20/MS. No differences in the levels of Jun-D and 
c-Jun were observed between NS20Y/MS and NS20Y cells 
(Fig. 1). 
To investigate whether the alterations in the expression of 
c-Fos and Jun-B proteins in persistently infected NS20Y/MS 
cells will affect the DNA-binding capacity of the AP-1 (Fos/ 
Jun) complex, electrophoretic mobility shift assay was per-
formed using three different TRE consensus oligonucleotides. 
The results clearly show that the binding of AP-1 to the 
monomeric TRE oligonucleotide (TRE monomer) was signifi-
Fig. 1. The expression of AP-1-related proteins in neuroblastoma 
cells persistently infected by MV. Total cell lysates of NS20Y/MS 
and NS20Y cells were prepared as described in Section 2 and sub-
jected to SDS-PAGE (50 ug/lane, each) followed by Western blot-
ting analysis with the appropriate antibodies. 
cantly decreased in the persistently infected NS20/MS cells 
(Fig. 2A). This decrease became more profound when an oli-
gonucleotide representing the tetramer of TRE was used. No 
such decrease was observed when the oligonucleotide repre-
senting TRE-like element derived from the c-jun promoter was 
used. This sequence slightly differs in sequence from TRE and 
binds heterodimers of c-Jun and cAMP responsive element 
binding (CREB) family member, i.e., ATF-2 [25]. Competi-
tion with the excess of the unlabeled monomeric TRE oligo-
nucleotide confirmed specificity of the binding (Fig. 2B). 
DNA binding capacity of another transcription factor, 
N F K B , was not affected by MV persistence (Fig. 2C). We 
have previously shown that the treatment of NS20Y/MS cells 
with anti-HA-MV antibodies resulted in down-regulation of 
MV mRNA and MV protein synthesis. To establish a linkage 
between the persistent infection and inhibition of AP-1 bind-
ing, we treated NS20Y/MS cells with anti-HA-MV antibodies. 
As depicted on Fig. 3A, this treatment restored AP-1 binding 
with concomitant decrease in the levels of MV N protein. To 
investigate whether the effect of MV on AP-1 binding is char-
acteristic to the persistent state, we tested the binding of nu-
clear proteins to the TRE tetramer in NS20Y cells acutely 
infected with MV. The synthesis of MV N protein was con-
firmed by Western blotting analysis with monoclonal anti-
MV N antibodies. We observed an increase in AP-1 binding 
in acutely infected cells comparing to the uninfected control in 
contrast to the marked decrease of AP-1 binding in persist-
ently infected NS20Y/MS cells (Fig. 3B). 
4. Discussion 
In this study we examined the effect of MV persistence on 
AP-1 factor DNA-binding capacity. Establishment of viral 
persistency is accompanied by alterations in the level of a 
number of proteins, both cellular and viral [5,6,26,27]. In re-
gard to the transcriptional factors, it means that any change 
in the level of these proteins may influence the composition of 
the active transcription complexes and, consequently, affect 
the affinity to the specific binding sites on DNA. Viruses 
can affect an activity of a variety of cellular transcription 
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Fig. 2. AP-1 binding is inhibited in NS20Y/MS cells. Nuclear lysates of NS20Y/MS and NS20Y cells were prepared as described [24] and ana-
lyzed by EMSA. A: Five |i.g of each extract was incubated with [32P]y-ATP end-labeled TRE probes. The reaction mixtures were resolved on 
5% PAGE, the gel was dried and exposed to X-ray film. B: Competition with 50 molar excess of unlabeled specific TRE monomeric and unla-
beled non-specific NFKB probes. C: Nuclear lysates (5 (ig) were incubated with [32P]y-ATP end-labeled NFkB probe and subjected to EMSA. 
factors and AP-1 complex is one of the major targets [28-30]. 
AP-1 DNA-binding activity is enhanced by Tax protein of 
HTLV-1 [31]. The hepatitis virus B transactivator protein 
Hbx stimulates a variety of cellular promoters through the 
increase in binding activity of AP-1 (Fos/Jun), AP-2 and 
N F K B transcription factors [32]. This strategy of an altered 
DNA-binding specificity by viruses may result in the modifi-
cation of a repertoire of cellular genes expressed during viral 
infection and affect functional activity of the infected cells. 
We have previously demonstrated that the level of c-fos 
mRNA is elevated in the persistently infected cells [5]. Our 
present results indicate that the level of c-Fos and Jun-B pro-
Fig. 3. Decreased AP-1 binding is characteristic to MV persisitence in neuroblastoma cells. A: NS20Y/MS and NS20Y cells were cultured for 
21 days in the presence of a mixture of three anti-MV H antibodies as described in Section 2. Nuclear lysates prepared from Ab-treated and 
untreated cells were subjected to EMSA (5 ug/lane, each) with [32P]y-ATP end-labeled TRE tetrameric probe. Total cell lysates prepared from 
Ab-treated and untreated cells were subjected to Western blotting analysis (50 ug/lane, each) with monoclonal anti- MV N antibody. B: NS20Y 
cells were acutely infected with MV as described in Section 2 and AP-1 binding was analyzed by EMSA with TRE tetramer as above. 
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teins were altered in the neuroblastoma cells persistently in-
fected with MV. Despite extensive data on the expression of c-
fos in a variety of cells, its role is not fully understood. Rapid 
induction of c-fos in the cells of neuronal origin in response to 
nerve growth factor, sensory stimulation and chemical agents 
indicates that it plays an important role in the responses of 
neuronal cells [33,34]. A number of nuclear proteins may bind 
c-Fos resulting in AP-1 complexes with different specificity. 
Regulatory systems which determine the exact composition 
of AP-1 in each particular situation are highly complex. 
AP-1 (Fos/Jun) binding to the TRE consensus sequence was 
markedly decreased in neuroblastoma cells persistently in-
fected neuroblastoma cells. This decrease was specific to the 
TRE consensus site since binding to the similar, but not iden-
tical, sequence originated from a c-jun promoter, which binds 
c-Jun/ATF-2 dimers, was not changed. Down-regulation of 
the MV mRNA and MV protein levels by neutralizing anti-
MV-HA antibodies in persistently infected cells restored TRE 
binding (Fig. 3A). The decrease in TRE binding may be a 
consequence of an accumulation of MV proteins in the in-
fected cells that affects the formation of different AP-1 dimers. 
Alternatively, it may be a manifestation of an adoptive re-
sponse of the cell to the persistent viral infection. To answer 
this question, we tested AP-1 binding in neuroblastoma cells 
acutely infected with MV. As can been seen from Fig. 3B, 
TRE binding was increased in acutely infected cells comparing 
to uninfected controls, in contrast to persistently infected cells 
which showed diminished AP-1 binding. However, both 
acutely and persistently infected cells expressed MV N protein 
at the comparative levels. Thus, the decrease of binding of 
nuclear proteins to the TRE consensus oligonucleotide ap-
pears to be the characteristic feature of the adaptive response 
of neuroblastoma cells to MV persistence. Alterations in the 
DNA-binding capacity, observed in persistently infected cells, 
were specific to the TRE element since no changes in N F K B 
were found. 
The molecular pathogenesis of the diseases associated with 
MV persistence in brain cells is poorly understood. No infec-
tious virus is formed in the persistent state and large amounts 
of nucleocapsid particles are accumulated in the cytoplasm 
[16]. We suggested that dwelling of a foreign substance such 
as virus or viral proteins in a cell cannot be inert. Rather, it 
starts as a cascade of pathological metabolic changes which 
are clinically 'silent' but develop into a serious disorder over 
time and eventually lead to the clinical manifestation charac-
teristic to SSPE, MIBE or other cerebral dysfunction. Note-
worthy, some clinical and pathological features of Alzheimer 
disease show a resemblance to viral infections [35-37]. 
A tissue culture model of neuroblastoma cell persistently 
infected with measles virus developed in our laboratory con-
firms the above prediction that the viral persistence affects 
intracellular communication events including gene expression 
[5,6,21]. Our results demonstrate that MV persistence is char-
acterized by changes in the level of AP-1 constituents, Fos and 
Jun, and by alterations in binding of nuclear complexes to the 
TRE element. These alterations may lead to the changes in the 
regulation of a variety of TRE-containing genes and may be 
characteristic feature of the adaptive response of the cell to 
the persistent viral infection. 
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